2307-1109

Aterotromboz = Atherothrombosis

Remedium, Ltd.

View prefix report (10.21518)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 86 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact86 DOIs
2

Add abstracts to 62 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact62 DOIs
3

Deposit reference lists for 46 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact46 DOIs

DOIs for this ISSN

Showing the top 5 of 141 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 FORMATION OF A«NEWBIFURCATION» IN PATIENTS WITH ATHEROSCLERO… (10.21518/2307-1109-2018-2-141-146)
ORCID
27.85 12
2 MANUAL THROMBOEXTRACTION IN PATIENTS WITH ACUTE MYOCARDIAL I… (10.21518/2307-1109-2016-1-39-49)
ORCID
25.00 9
3 HEPARIN-INDUCED THROMBOCYTOPENIA (REVIEW) (10.21518/2307-1109-2019-1-99-114)
ORCID
22.58 7
4 THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONV… (10.21518/2307-1109-2019-2-68-79)
Abstract
19.45 5
5 Intracardiac thrombosis: frequency, risk factors and place o… (10.21518/2307-1109-2020-1-134-152)
Abstract
19.45 5
6 Long-term outcomes of coronary artery bypass graft surgery i… (10.21518/2307-1109-2021-11-2-30-43)
Abstract
19.45 5
7 SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS (10.21518/2307-1109-2016-1-81-94)
ORCID
17.47 4
8 Thrombus of left atrium and/or its appendage in nonvalvular… (10.21518/2307-1109-2020-1-56-70)
Abstract
17.47 4
9 THE ROLE OF RADIATION DIAGNOSTIC TECHNIQUES IN THE DIAGNOSIS… (10.21518/2307-1109-2016-1-16-25)
ORCID
15.05 3
10 PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON T… (10.21518/2307-1109-2018-2-115-129)
ORCID
15.05 3
11 CONSIDERING QUESTION OF SAFETY OF DIRECT ORAL ANTICOAGULANTS… (10.21518/2307-1109-2018-2-54-67)
ORCID
15.05 3
12 PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH… (10.21518/2307-1109-2019-1-8-24)
ORCID
15.05 3
13 IMMEDIATE AND LONGTERM RESULTS OF ENDOVASCULAR STENT-GRAFTIN… (10.21518/2307-1109-2018-2-135-140)
ORCID
11.93 2
14 IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE… (10.21518/2307-1109-2018-2-147-158)
ORCID
11.93 2
15 PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIEN… (10.21518/2307-1109-2019-2-46-54)
Abstract
11.93 2
16 COMPARATIVE CHARACTERISTICS OF MULTIMORBIDITY, DRUG TREATMEN… (10.21518/2307-1109-2019-2-56-67)
Abstract
11.93 2
17 Risk factors venous and arterial thrombosis in young women o… (10.21518/2307-1109-2020-1-18-32)
Abstract
11.93 2
18 Clinical case of a paradoxical embolism that caused an acute… (10.21518/2307-1109-2020-2-161-168)
ORCID
11.93 2
19 Sulodexide as pharmacotherapy for protection of endothelium… (10.21518/2307-1109-2021-11-2-6-17)
Abstract
11.93 2
20 DETECTING PAINLESS MYOCARDIAL ISCHEMIA IN A PATIENT WITH RE… (10.21518/2307-1109-2016-1-101-107)
ORCID
7.53 1
21 NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOS… (10.21518/2307-1109-2016-1-5-15)
ORCID
7.53 1
22 ГИПОАГРЕГАЦИОННЫЙ ЭФФЕКТ У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА С ПОДЪ… (10.21518/2307-1109-2016-2-54-60)
ORCID
7.53 1
23 HOW TO TREAT VTEC IN CANCER PATIENTS IN THE ACUTE PERIOD? EX… (10.21518/2307-1109-2018-2-28-35)
ORCID
7.53 1
24 ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBI… (10.21518/2307-1109-2018-2-68-74)
ORCID
7.53 1
25 PRASUGREL: FREQUENTLY ASKED QUESTIONS FROM PRACTITIONERS (10.21518/2307-1109-2019-1-148-158)
ORCID
7.53 1
26 CLINICAL OUTCOMES OF ENDOVASCULAR INTERVENTIONS IN DIABETIC… (10.21518/2307-1109-2019-1-25-35)
ORCID
7.53 1
27 POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT IN… (10.21518/2307-1109-2019-1-72-81)
ORCID
7.53 1
28 CLINICAL CASE OF RESUMPTION OF ANTICOAGULANT THERAPY AFTER I… (10.21518/2307-1109-2019-1-82-91)
ORCID
7.53 1
29 CASE OF LEFT ATRIUM INTRAMURAL HEMATOMA AFTER PERCUTANEOUS C… (10.21518/2307-1109-2019-2-80-92)
Abstract
7.53 1
30 Atrial fibrillation in elderly patients. Features of using r… (10.21518/2307-1109-2020-1-9-16)
Abstract
7.53 1
31 Characteristics of patients with active cancer and venous th… (10.21518/2307-1109-2021-11-2-44-54)
Abstract
7.53 1
32 SAFETY ISSUES IN THE TREATMENT OF PATIENTS TAKING DABIGATRA… (10.21518/2307-1109-2016-1-108-112)
References ORCID
0.00 0
33 LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF… (10.21518/2307-1109-2016-1-26-38)
ORCID
0.00 0
34 WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY (10.21518/2307-1109-2016-1-50-58)
ORCID
0.00 0
35 DURATION OF DUAL ANTIPLATELET THERAPY (10.21518/2307-1109-2016-1-59-68)
ORCID
0.00 0
36 EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PR… (10.21518/2307-1109-2016-1-69-80)
ORCID
0.00 0
37 WHAT COULD HAVE BEEN DONE DIFFERENTLY? A PATIENT WITH ACUT… (10.21518/2307-1109-2016-1-95-100)
ORCID
0.00 0
38 ВЛИЯНИЕ КОМБИНИРОВАННОЙ ТЕРАПИИ НА ЦЕНТРАЛЬНОЕ АРТЕРИАЛЬНОЕ… (10.21518/2307-1109-2016-2-)
ORCID
0.00 0
39 ПРИМЕНЕНИЕ ПИТАВАСТАТИНА У ЛИЦ ПОЖИЛОГО И СТАРЧЕСКОГО ВОЗРАС… (10.21518/2307-1109-2016-2-106-116)
ORCID
0.00 0
40 ВОПРОСЫ БЕЗОПАСНОСТИ ТЕРАПИИ БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРД… (10.21518/2307-1109-2016-2-117-123)
References ORCID
0.00 0
41 ИННОВАЦИЯ В МЕДИКАМЕНТОЗНОМ ЛЕЧЕНИИ ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ… (10.21518/2307-1109-2016-2-14-26)
ORCID
0.00 0
42 ИСПОЛЬЗОВАНИЕ АНТИТРОМБОТИЧЕСКИХ ПРЕПАРАТОВ ПРИ ОСТРОМ КОРОН… (10.21518/2307-1109-2016-2-27-35)
ORCID
0.00 0
43 ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ЭНОКСАПАРИНА ПРИ ОСТРОМ КОРОНАРНОМ СИ… (10.21518/2307-1109-2016-2-36-45)
ORCID
0.00 0
44 АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМ… (10.21518/2307-1109-2016-2-46-53)
ORCID
0.00 0
45 МЕСТО И ЗНАЧЕНИЕ НАБЛЮДАТЕЛЬНЫХ ИССЛЕДОВАНИЙ НОАК У ПАЦИЕНТО… (10.21518/2307-1109-2016-2-61-64)
References ORCID
0.00 0
46 СОВРЕМЕННЫЕ ПОДХОДЫ К СТРАТИФИКАЦИИ РИСКА БОЛЬНЫХ, ПОДВЕРГАЕ… (10.21518/2307-1109-2016-2-65-80)
ORCID
0.00 0
47 CОВРЕМЕННЫЕ СТРАТЕГИИ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖН… (10.21518/2307-1109-2016-2-7-13)
ORCID
0.00 0
48 СНИЖЕНИЕ РИСКА СЕРДЕЧНО-СОСУДИСТОЙ СМЕРТНОСТИ И ИНСУЛЬТА У П… (10.21518/2307-1109-2016-2-81-88)
ORCID
0.00 0
49 ПРОФИЛАКТИКА ПОВТОРНОГО НЕКАРДИОЭМБОЛИЧЕСКОГО ИШЕМИЧЕСКОГО И… (10.21518/2307-1109-2016-2-89-97)
ORCID
0.00 0
50 «НЕПОТЕРЯННОЕ ВРЕМЯ» В ПРОФИЛАКТИКЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРД… (10.21518/2307-1109-2016-2-98-105)
ORCID
0.00 0